SynthesisHypertension research : official journal of the Japanese Society of Hypertension2025
Intensive blood pressure-lowering treatment to prevent cardiovascular events in patients with diabetes: a systematic review and meta-analysis.
Synthesis in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Blood pressure targets for hypertension in people with diabetes mellitus.The Cochrane database of systematic reviews · 2026Pooled it
- [Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)].Wiener klinische Wochenschrift · 2026Guideline
- Intensive blood pressure control in type 2 diabetes: a meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026Pooled it
- The conservative-challenging paradigm of antihypertensive therapy in JSH2025: a comparative perspective with contemporary Western guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Advancing evidence-based blood pressure targets in JSH2025.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Risk management of cardiovascular disease in older patients with diabetes.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- The JSH Morning Hypertension Eradication Program Project.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Achievement rate of blood pressure control <130/80 mmHg as the core metric of implementation hypertension, based on the new JSH2025 and AHA/ACC2025 guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- The new blood pressure target, a new era: individualized management and precision rooted in clinical decision in JSH2025.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- JSH2025 guidelines new viewpoints.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Key highlights of the Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of intensive blood pressure (BP) reduction on the prevention of cardiovascular events in patients with diabetes remains unclear. This study evaluated the impact of intensive BP-lowering on cardiovascular events in patients with diabetes compared to standard treatment. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, comparing intensive treatment (target systolic BP < 130 mmHg or diastolic BP < 80 mmHg) with standard treatment in patients with diabetes. Eligible studies were identified through Ovid MEDLINE, Cochrane Library, and Ichushi. Outcomes included cardiovascular events, coronary artery disease, stroke, all-cause and cardiovascular death, and serious adverse events. Data were analyzed using a random-effects model. Sensitivity analyses were performed to assess the effects of systolic and diastolic BP targets separately. The search identified eight eligible trials comprising 16634 patients with diabetes. Intensive BP-lowering treatment significantly reduced cardiovascular events (risk ratio: 0.848; 95% confidence interval: 0.760, 0.947) and stroke (risk ratio: 0.705; 95% confidence interval: 0.541, 0.918), but not coronary artery disease or all-cause death in analyses including J-DOIT3 trial. Sensitivity analyses showed that DBP-targeted treatment was not associated with the risk of cardiovascular events. Incorporating the latest RCT strengthened the association between intensive treatment and reduced coronary artery disease risk, without significantly increasing the risk of serious adverse events. These findings recommend an intensive BP-lowering strategy targeting SBP < 130 mmHg or DBP < 80 mmHg to prevent cardiovascular events, particularly stroke, in patients with diabetes.
Indexed as
Identifiers
40269228What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.